- Home
- DXR vs OKUR Comparison
DXR vs OKUR Comparison
Compare DXR & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- OKUR
- Stock Information
- Founded
- DXR 1970
- OKUR 2011
- Country
- DXR United States
- OKUR United States
- Employees
- DXR N/A
- OKUR N/A
- Industry
- DXR Medical/Dental Instruments
- OKUR
- Sector
- DXR Health Care
- OKUR
- Exchange
- DXR Nasdaq
- OKUR NYSE
- Market Cap
- DXR 36.4M
- OKUR 34.9M
- IPO Year
- DXR N/A
- OKUR N/A
- Fundamental
- Price
- DXR $9.65
- OKUR $2.39
- Analyst Decision
- DXR Strong Buy
- OKUR Strong Buy
- Analyst Count
- DXR 1
- OKUR 4
- Target Price
- DXR $25.00
- OKUR $32.25
- AVG Volume (30 Days)
- DXR 6.0K
- OKUR 79.2K
- Earning Date
- DXR 01-01-0001
- OKUR 08-14-2025
- Dividend Yield
- DXR N/A
- OKUR N/A
- EPS Growth
- DXR 86.16
- OKUR N/A
- EPS
- DXR 0.11
- OKUR N/A
- Revenue
- DXR $119,714.00
- OKUR N/A
- Revenue This Year
- DXR N/A
- OKUR N/A
- Revenue Next Year
- DXR N/A
- OKUR N/A
- P/E Ratio
- DXR $90.07
- OKUR N/A
- Revenue Growth
- DXR N/A
- OKUR N/A
- 52 Week Low
- DXR $6.55
- OKUR $1.70
- 52 Week High
- DXR $10.00
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- DXR 63.02
- OKUR N/A
- Support Level
- DXR $8.68
- OKUR N/A
- Resistance Level
- DXR $9.79
- OKUR N/A
- Average True Range (ATR)
- DXR 0.46
- OKUR 0.00
- MACD
- DXR 0.02
- OKUR 0.00
- Stochastic Oscillator
- DXR 89.55
- OKUR 0.00
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.